0000899243-19-030174.txt : 20191230 0000899243-19-030174.hdr.sgml : 20191230 20191230171444 ACCESSION NUMBER: 0000899243-19-030174 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191226 FILED AS OF DATE: 20191230 DATE AS OF CHANGE: 20191230 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sheehy Douglas T. CENTRAL INDEX KEY: 0001488637 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37519 FILM NUMBER: 191317315 MAIL ADDRESS: STREET 1: C/O AIMMUNE THERAPEUTICS, INC. STREET 2: 8000 MARINA BOULEVARD, SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc. CENTRAL INDEX KEY: 0001631650 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452748244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 BUSINESS PHONE: (650) 614-5220 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 FORMER COMPANY: FORMER CONFORMED NAME: Allergen Research Corp DATE OF NAME CHANGE: 20150123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-26 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001488637 Sheehy Douglas T. AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005-1884 0 1 0 0 See Remarks Common Stock, $0.0001 par value 2019-12-26 4 M 0 10000 12.95 A 55668 D Common Stock, $0.0001 par value 2019-12-26 4 S 0 10000 33.0322 D 45668 D Stock Option (right to buy) 12.95 2019-12-26 4 M 0 10000 0.00 D 2026-04-29 Common Stock 10000 53649 D The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by Reporting Person. Includes 29,617 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Includes 12,500 restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $33.00 to $33.15 per share. Information on the actual numbers of shares sold at each sale price can be obtain from Issuer upon request. The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on April 4, 2017 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to Reporting Person's continued service relationship with Issuer on each such vesting date. General Counsel and Corporate Secretary /s/ Douglas T. Sheehy 2019-12-30